- Home
- ABUS
as 12-20-2024 4:00pm EST
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | WARMINSTER |
| Market Cap: | 697.3M | IPO Year: | N/A |
| Target Price: | $5.50 | AVG Volume (30 days): | 903.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.21 - $4.72 | Next Earning Date: | 11-06-2024 |
| Revenue: | $6,742,000 | Revenue Growth: | -69.69% |
| Revenue Growth (this year): | -65.24% | Revenue Growth (next year): | -15.97% |
Latest Arbutus Biopharma Corporation News
ABUS Breaking Stock News: Dive into ABUS Ticker-Specific Updates for Smart Investing
Insider Monkey
16 days ago
Here’s Why Arbutus (ABUS) Surged in Q3
Business Wire
19 days ago
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
GlobeNewswire
a month ago
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
MT Newswires
a month ago
Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results
GlobeNewswire
a month ago
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
GlobeNewswire
a month ago
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
GlobeNewswire
a month ago
Arbutus to Present at Jefferies London Healthcare Conference
GuruFocus.com
a month ago
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...
Compare ABUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABUS Arbutus Biopharma Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.